BACKGROUND: The purpose of this phase II trial was to evaluate the tolerability, safety, and efficacy of a non-5-fluorouracil (5-FU)-based induction chemotherapy followed by chemoradiotherapy (CRT) for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). METHODS: Sixty patients with stage III to IV HNSCC were treated with induction paclitaxel and cisplatin (TP; paclitaxel 175 mg/m(2) and cisplatin 80 mg/m(2) , 3 cycles) followed by CRT (cisplatin 100 mg/m(2) ; D1, 22, and 43 of radiotherapy). RESULTS: Fifty-six patients (93.3%) completed 3 cycles of induction TP (no treatment-related deaths), 52 (86.7%) completed definitive CRT per protocol (adverse event [AE] grade ≥2 in 53.3%). The overall response rate after induction TP was 82.5% for patients with resectable disease and 55.5% for unresectable disease (p = .023), and complete response (CR) rate after CRT was 70.0% for patients with resectable disease and 30.0% for unresectable disease (p = .005). CONCLUSION: Induction TP followed by cisplatin based-CRT was well-tolerated, safe, and had high overall response rate in selected patients with locally advanced HNSCC.
BACKGROUND: The purpose of this phase II trial was to evaluate the tolerability, safety, and efficacy of a non-5-fluorouracil (5-FU)-based induction chemotherapy followed by chemoradiotherapy (CRT) for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). METHODS: Sixty patients with stage III to IV HNSCC were treated with induction paclitaxel and cisplatin (TP; paclitaxel 175 mg/m(2) and cisplatin 80 mg/m(2) , 3 cycles) followed by CRT (cisplatin 100 mg/m(2) ; D1, 22, and 43 of radiotherapy). RESULTS: Fifty-six patients (93.3%) completed 3 cycles of induction TP (no treatment-related deaths), 52 (86.7%) completed definitive CRT per protocol (adverse event [AE] grade ≥2 in 53.3%). The overall response rate after induction TP was 82.5% for patients with resectable disease and 55.5% for unresectable disease (p = .023), and complete response (CR) rate after CRT was 70.0% for patients with resectable disease and 30.0% for unresectable disease (p = .005). CONCLUSION: Induction TP followed by cisplatin based-CRT was well-tolerated, safe, and had high overall response rate in selected patients with locally advanced HNSCC.
Authors: C Tilden Hagan; Cameron Bloomquist; Samuel Warner; Nicole M Knape; Isaiah Kim; Hayley Foley; Kyle T Wagner; Sue Mecham; Joseph DeSimone; Andrew Z Wang Journal: J Control Release Date: 2022-02-22 Impact factor: 11.467
Authors: Lidia Maria Rebolho Batista Arantes; Ana Carolina Laus; Matias Eliseo Melendez; Ana Carolina de Carvalho; Bruna Pereira Sorroche; Pedro Rafael Martins De Marchi; Adriane Feijó Evangelista; Cristovam Scapulatempo-Neto; Luciano de Souza Viana; André Lopes Carvalho Journal: Oncotarget Date: 2017-02-07
Authors: Aline Lauda Freitas Chaves; Ana Ferreira Castro; Gustavo Nader Marta; Gilberto Castro Junior; Robert L Ferris; Raúl Eduardo Giglio; Wojciech Golusinski; Philippe Gorphe; Sefik Hosal; C René Leemans; Nicolas Magné; Hisham Mehanna; Ricard Mesía; Eduardo Netto; Amanda Psyrri; Assuntina G Sacco; Jatin Shah; Christian Simon; Jan B Vermorken; Luiz Paulo Kowalski Journal: Oral Oncol Date: 2020-04-24 Impact factor: 5.337